NEW RESOURCES AND SURVEILLANCE GUIDES TO SUPPORT EARLY DETECTION OF PANCREATIC CANCER Pancare Foundation disseminates material commissioned by Cancer Australia and developed by UQ and Uni of Melbourne
With
Dr Michael KC Lee,
Medical Oncologist,
Peter MacCallum Cancer Centre
Dr Mark Buzza,
Head of Research, Innovation and Advocacy,
Pancare Foundation
SEGMENT
Filmed in Melbourne | February 2026
Pancreatic cancer remains one of Australia’s deadliest cancers, with five-year survival rates hovering at just 14%, with little improvement over several decades. Often called the ‘silent killer’, the disease frequently presents with minimal or vague symptoms, resulting in late diagnoses and poor outcomes. Pancare Foundation is leading the rollout of new clinical resources and surveillance guides to support healthcare professionals in identifying at-risk patients and promoting early detection.
More than 4,500 Australians are diagnosed with pancreatic cancer each year, and the disease is projected to become the second leading cause of cancer-related death by 2030. Despite advances in treatment, the lack of a population-level national screening program, as there is for bowel cancer for example, means that healthcare professionals play a critical role in early detection and patient education.
“Early identification is key,” said Dr Mark Buzza, Head of Research, Innovation and Advocacy, Pancare Foundation. “These new resources provide practical guidance for clinicians on risk assessment, surveillance protocols, and patient communication. By equipping healthcare professionals with the latest evidence-based tools, we can improve detection rates and ultimately patient outcomes.”
The resources highlight key risk factors to be aware of including a family history of pancreatic cancer, smoking, long-term diabetes, chronic pancreatitis, heavy alcohol use, and obesity.
Importantly, pancreatic cancer can also occur in patients without obvious risk factors. Developed by the University of Queensland (alongside their contributors), the new surveillance guides offer clear recommendations for monitoring high-risk individuals, identifying early symptoms, and coordinating referral pathways for diagnostic investigations.
In addition, the University of Melbourne provides pain and palliative care education resources for healthcare professionals, ensuring clinicians are equipped to support patients throughout the continuum of care.
Source: Adapted from Pancare Foundation media release
You Might also like
-
Lasers in dental treatment without needles and drills
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.
-
Targeted National Lung Cancer Screening Program commences in 2025
In February 2025, Australian Health Journal spoke with Mark Brooke, Chief Executive Officer of Lung Foundation Australia, at the 10th Australian Lung Cancer Conference in Adelaide, on the upcoming commencement of the National Lung Cancer Screening Program (NLCSP)
-
Clinical pain neuroscientist talks about how the brain processes pain information
Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.
Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.
Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.